On Jul. 7, 2026, the U.S. Food and Drug Administration has approved Vera Therapeutics’ drug to treat patients with a ​potentially life-threatening kidney disease, the regulator said, sending its ‌shares up 6.8% in afternoon trading.

The drug Trutakna is a self-administered injectable treatment approved for patients with immunoglobulin A nephropathy, also known as Berger’s disease, which causes abnormal protein buildup in ​the kidneys and could eventually lead to the organ’s failure.

Trutakna is the ​first and only drug that targets the immune-system proteins BAFF and ⁠APRIL, which are involved in the production of disease-causing antibodies in IgA ​nephropathy and other autoimmune disorders.

The accelerated approval is based on a late-stage study in which ​the drug reduced protein levels in the urine by 42% compared with placebo after 36 weeks of treatment. Patients receiving the drug saw a 46% decline from baseline.

The trial is continuing ​to evaluate its effect on kidney function, measured by estimated glomerular filtration rate (eGFR), ​with data now expected in the third quarter of 2026, ahead of the previous 2027 timeline.